Proteonomix Inc. deal

Proteonomix received an exclusive, worldwide license from CSO Ian McNiece to anti-tumor technology relating to primary human cells that secrete a factor capable of inhibiting growth and causing death of tumor cells. The technology consists of methods for isolation and propagation of the primary human cells, gene profiles obtained from the cells identifying candidate microRNAs, and growth factor genes and methods for generating culture media conditioned by these cells for isolation of the inhibitory factor. McNiece received $100,000 up front. McNiece and a third party related to the technology are eligible for milestone payments of up to $950,000 plus 50,000 Proteonomix common shares, as well as 3% royalty on sales. ...